<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500265</url>
  </required_header>
  <id_info>
    <org_study_id>I10006 HBVSECURE</org_study_id>
    <nct_id>NCT01500265</nct_id>
  </id_info>
  <brief_title>Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus</brief_title>
  <acronym>HBVSECURE</acronym>
  <official_title>Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nucleotide analogues are associated in the long term with a risk of proximal tubular
      nephropathy (PT) with loss of phosphate, and, when compensatory mechanisms are overwhelmed,
      with osteopenia or osteoporosis. This toxicity has been particularly documented for tenofovir
      (TDF) in HIV disease, but its prevalence varies widely in the literature and is mainly
      associated with comorbidities: on average this prevalence is 0.39% after 48 weeks with
      exceptional cases of Fanconi syndrome described. In HBV monoinfection after 60 months of
      treatment with TDF, an 11% decrease of creatinine clearance (CreatCl) is observed. A single
      study showed a significant increase in creatinine level with entecavir (ETV) therapy, a
      second-generation nucleoside, hitherto not described as nephrotoxic. Furthermore, if the
      direct renal toxic effect characteristic of HIV in the kidney is well known, the role of HBV
      is less clear. Thus, HBV treatment appears to have a renal protective effect. The monitoring
      tools recommended by the SPC, CreatCl and plasma phosphorus level are late markers of tubular
      damage. The threshold of phosphate tubular reabsorption (TmPi/GFR) and the fractional
      excretion of uric acid (FEUA) are unexpensive early screening tools. However, the long-term
      evolution of this subclinical tubular involvement in HBV monoinfection is not known.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      260 naive untreated patients, 220 patients treated with TDF and 220 patients treated with ETV
      and consecutively recruited in this interventional study, will have at baseline and every
      three months, a determination of phosphorus, creatinine, uric acid in plasma and urine
      samples for determination of TMPi / GFR and FEUA, and an evaluation of urinary calcium level.
      Depending on local opportunities, every six months, a urine sample will be stored in a
      declared biological collection to perform β2-microglobuline and cystatin dosage. A 25-OHD3
      and PTH dosage will be conducted annually. A sample of genomic DNA will be collected after
      informed consent of the patient from a saliva sample (Saliva autocollection kits) in order to
      investigate genetic polymorphism in transporters responsible for the renal elimination of TDF
      and ETV. A serum sample will be stored at baseline, at one year and at endpoint for the
      retrospective dosage of bone markers (bone PAlk, PINP and CTX).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the prevalence of &quot;subclinical&quot; proximal tubular abnormalities</measure>
    <time_frame>2 years</time_frame>
    <description>to compare at 2 years the prevalence of &quot;subclinical&quot; proximal tubular abnormalities (TmPi/GFR and FEUA) in 3 groups of HBV monoinfected patients treated with TDF, ETV or untreated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the prevalence at baseline of &quot;subclinical&quot; proximal tubular abnormalities</measure>
    <time_frame>1 day</time_frame>
    <description>to describe the prevalence at baseline, and the cumulative incidence of these abnormalities during the follow-up and determine the proportion of patients who present at 2 years an impaired CreatCl, an hypophosphatemia and an hypercalciuria (suggesting a bone impact), according to the presence or absence of &quot;subclinical&quot; proximal tubular abnormalities.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">216</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Renal Failure With Tubular Necrosis</condition>
  <arm_group>
    <arm_group_label>Patient naive</arm_group_label>
    <description>Patient with hepatitis B virus naive untreated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with TDF</arm_group_label>
    <description>Patient with hepatits B treated with Tenofovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with ETV</arm_group_label>
    <description>Patient with hepatitis B virus treated with Entecavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>plasma and urine samples, sample with ADN</intervention_name>
    <description>plasma and urine samples every three months Sample with ADN at baseline</description>
    <arm_group_label>Patient naive</arm_group_label>
    <arm_group_label>Patient with TDF</arm_group_label>
    <arm_group_label>Patient with ETV</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and urine samples for determination of TMPi / GFR and FEUA A sample of genomic DNA
      will be collected after informed consent of the patient from a saliva sample (Saliva
      autocollection kits) in order to investigate genetic polymorphism in transporters responsible
      for the renal elimination of TDF and ETV.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with hepatitis B virus
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patients with chronic HBV virus monoinfected

          -  For groups of patients treated: Patients with an indication of ETV or TDF

          -  For the group of naive patients: treatment-naive patients who have no indication of
             treatment (or do not want) for the duration of the study

          -  globular filtration rate (GFR) ≥ 50 ml / min / 1.73 m2 with no known cause of renal
             disease

          -  Patients who have given their informed and written informed consent

          -  Women of childbearing potential with an effective method of contraception without
             interruption for the duration of the research and during the 4 months after stopping
             treatment

        Exclusion Criteria:

          -  Patients co-infected with HIV, hepatitis C or hepatitis Delta

          -  Patients who have already received the TDF in the group to receive the TDF and having
             already received ETV in the group to receive ETV

          -  Patient with a GFR &lt;50 ml / min / 1.73 m2 or with known causes of renal disease

          -  Patient with hypophosphatemia &lt;0.48 mmol / l

          -  Patients with hepatocellular carcinoma (diagnosed or suspected)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Laennec de Creil</name>
      <address>
        <city>Creil</city>
        <zip>60109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Hyères</name>
      <address>
        <city>Hyères</city>
        <zip>83407</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Roche sur Yon</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille - Hôpital Huriet</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Fédération Hépatologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut Levêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Point à Pitre</name>
      <address>
        <city>Point à Pitre</city>
        <zip>97159</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tours - Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hôpital Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2011</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis B virus</keyword>
  <keyword>early screening tools</keyword>
  <keyword>renal proximal tubular tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

